# Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL

> **NCT05695313** · PHASE2 · RECRUITING · sponsor: **Centre Georges Francois Leclerc** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** OnLife®
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05695313
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05695313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05695313, "Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05695313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*